Explore our industrial chemical portfolio delivered with full quality compliance and reliable global fulfillment.
A benchmark innovation in targeted oncology designed for central nervous system blood-brain barrier permeability.
AZD3759 (chemically known as Zorifertinib, CAS Registry Number: 1626371-35-3) represents a major breakthrough in targeted cancer therapies. It is an orally bioavailable, reversible, non-ATP competitive Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI). Unlike early-generation EGFR TKIs such as Gefitinib or Erlotinib, AZD3759 was rationally engineered specifically to achieve maximal blood-brain barrier (BBB) penetration without being actively effluxed by key P-glycoprotein (P-gp) or Breast Cancer Resistance Protein (BCRP) transporters.
In non-small cell lung cancer (NSCLC) patients harboring EGFR sensitizing mutations (such as Exon 19 deletions or L858R point mutations), central nervous system (CNS) metastases—including brain metastases (BM) and leptomeningeal metastases (LM)—present an enormous clinical burden. AZD3759 exhibits an outstanding free brain-to-plasma concentration ratio ($K_{pu,uu}$), ensuring therapeutic concentrations within the central nervous system parenchyma and cerebrospinal fluid (CSF).
| Analytical Parameter | Testing Specification | Typical Batch Result (Gentolex Standard) | Analytical Method |
|---|---|---|---|
| Chemical Purity | ≥ 99.0% (Area Percent) | 99.65% | HPLC-UV (254nm / 304nm) |
| Individual Impurity | ≤ 0.15% | < 0.05% | High Performance Liquid Chromatography |
| Total Impurities | ≤ 1.0% | 0.35% | HPLC Quantitative Analysis |
| Water Content (Karl Fischer) | ≤ 0.5% | 0.18% | Volumetric KF Titration |
| Heavy Metals Content | ≤ 10 ppm | Conforms (< 5 ppm) | ICP-MS (Inductively Coupled Plasma) |
| Residual Solvents | Meets ICH Q3C Guidelines | Passes Standard Limits | GC-Headspace Analysis |
| Structural Identification | Matches Reference Standard | Confirmed Structure | 1H-NMR, LC-MS, FT-IR Spectroscopy |
Evaluating clinical progression, market drivers, and the growing global demand for high-tier EGFR TKIs.
Over 40% of patients diagnosed with advanced EGFR-mutated NSCLC develop central nervous system metastases during their disease course. First- and second-generation TKIs exhibit restricted BBB translocation, leading to systemic control but CNS disease progression. AZD3759 targets this exact biological hurdle.
With multi-center Phase I, II, and pivotal Phase III trials evaluating Zorifertinib across Asian and Western cohorts, demand for active pharmaceutical ingredients (APIs) and research-grade reference materials has surged globally among biotech firms, academic centers, and contract research organizations (CROs).
Pharma organizations are restructuring API procurement to work directly with qualified primary manufacturers in China. Direct sourcing offers superior batch traceability, shorter lead times, and seamless regulatory file integration (DMF / CEP compliance).
Why modern global pharmaceutical leaders rely on Chinese chemical manufacturing ecosystem advantages.
China holds the world’s most fully integrated chemical industrial supply chain network. For complex quinazoline derivatives like AZD3759, access to foundational raw materials, advanced intermediates (e.g., 4-chloro-7-substituted quinazolines), and specialized reagents (such as 4-dimethylaminobut-2-enoic acid precursors) is centralized within regional chemical infrastructure hubs.
This localized cluster minimizes intermediate shipping delays, reduces raw material cost spikes, and allows rapid scale-up from pilot multi-gram batches to metric-ton commercial reactor quantities.
Leading Chinese chemical producers have transitioned traditional batch synthesis to modern continuous flow technology for hazardous or heat-sensitive chemical transformations. Micro-channel reactors ensure exact temperature control, minimal side-product generation, superior enantiomeric purity maintenance, and higher overall chemical yields for active target molecules like Zorifertinib.
From milligrams for initial bioassay evaluation to multi-kilogram lots for formulation development and clinical registration batches.
Operational procedures compliant with international cGMP, ISO 9001, and ISO 14001 guidelines, complete with full ICH stability testing suites.
Every batch undergoes standard multi-instrument testing including 400MHz NMR, LC-MS, HPLC purity assays, chiral purity evaluation, heavy metal ICP-MS, and residual solvent GC analysis.
Connecting global health and industrial innovation with high-grade active ingredients and custom synthesis capability.
Gentolex’s overarching mission is to build robust, seamless channels connecting global markets with high-caliber chemical solutions and certified standard products. Today, Gentolex Group serves valued clinical, institutional, and industrial clients across more than 10 countries, featuring dedicated regional representative teams established in strategic markets including Mexico and South Africa.
Our facility spans an overall international standard construction footprint of 250,000 square meters, enabling flexible, highly scalable, and cost-efficient batch production. We specialize in supply solutions for Peptide APIs, Small Molecule APIs, Custom Synthesis, Finished Dosage Form (FDF) License Out, Technical Consultation, Lab Setup, and Comprehensive Sourcing.
Comprehensive solid-phase and liquid-phase synthesis for standard and modified peptide sequences.
High-purity small molecule APIs, advanced intermediates, and custom fine chemicals under cGMP.
Out-licensing rights and technical registration dossiers for international formulation commercialization.
Streamlined single-point procurement models eliminating multi-vendor tracking complexities for buyers.
Ensuring complete documentation, regulatory alignment, and risk-managed cold-chain distribution worldwide.
We furnish clients with exhaustive quality dossiers necessary for regulatory filing. Deliverables include Certificates of Analysis (COA), Material Safety Data Sheets (MSDS), Method Validation Reports, Impurity Profiling Data, and DMF filing documentation upon request.
Every batch of AZD3759 undergoes strict Quality Control (QC) inspection prior to release. Retention samples are archived under controlled temperature conditions for 5+ years, providing complete back-traceability for international audits.
Equipped with deep expertise in customs clearance and international air/sea freight handling. Delicate or sensitive compounds are packed in specialized insulated containers with real-time temperature tracking to prevent degradation during transit.
Stay informed with the latest updates from our research team and API manufacturing developments.
Key technical, regulatory, and commercial insights for procuring AZD3759 (Zorifertinib).
AZD3759 (CAS: 1626371-35-3) is an orally bioavailable, potent, reversible EGFR tyrosine kinase inhibitor (TKI). Its key structural differentiation lies in its ability to penetrate the blood-brain barrier (BBB) without being effluxed by P-gp or BCRP transporters. It targets wild-type and mutant EGFR (L858R and Exon 19 del), specifically addressing NSCLC patients with CNS or leptomeningeal metastases.
China maintains an end-to-end supply chain for quinazoline-based small molecules, from raw chemical precursors to continuous-flow API reactors. Sourcing directly from certified Chinese manufacturers provides up to 40-60% cost efficiencies while ensuring compliance with international cGMP standards, full analytical backing (NMR, LC-MS, HPLC), and flexible batch scaling.
Each batch comes standard with a full analytical dossier including: Certificate of Analysis (COA), High-Performance Liquid Chromatography (HPLC) chromatograms, Mass Spectrometry (MS) readout, 1H-NMR spectra, and Safety Data Sheets (MSDS). Method validation reports and stability data under ICH conditions are available for industrial clients.
Our standard commercial batch purity is guaranteed at ≥ 99.0% by HPLC. For specialized analytical reference standard requirements or advanced formulation studies, custom purification up to ≥ 99.5% with single-impurity control below 0.05% can be supplied upon request.
AZD3759 API powder should be stored in tightly sealed containers protected from light and moisture. For short-term storage (under 3 months), store at 2°C to 8°C. For long-term shelf-life preservation (up to 36 months), store at -20°C in an desiccated environment under nitrogen blanket filling.
We offer flexible scale options: R&D sample quantities start from 1g to 100g, while pilot commercial batches range from 1kg to 50kg+. In-stock inventory typically dispatches within 3-5 business days via temperature-monitored air express shipping. Custom synthesis scale-up runs require 3 to 6 weeks.
Gentolex handles export logistics in full compliance with international chemical transport regulations (IATA / IMDG). All packaging features certified outer drums, ESD moisture barrier bags, and proper chemical classification labeling to guarantee seamless customs clearance across European, North American, and Asian ports.
Yes. Supported by our 250,000 m² infrastructure and internal chemical R&D lab, we provide custom synthesis services for isotope-labeled AZD3759, specific metabolite standards, structural analogs, or quinazoline scaffold modifications tailored to client research protocol requirements.
Collaborating with accredited global institutions, logistics partners, and international quality standards.
Discover our complementary target portfolio manufactured under rigorous analytical quality control.
